2024年卵巢癌治疗研究进展盘点  

Year-end review of treatment of ovarian cancer in 2024

作　　者：杨洁 向阳 Yang Jie;Xiang Yang(Department of Obstetrics and Gynecology,National Clinical Research Center for Obstetrics&Gynecologic Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院、北京协和医院妇产科、国家妇产疾病临床医学研究中心,北京100730

出　　处：《肿瘤综合治疗电子杂志》2025年第1期68-72,共5页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：国家重点研发计划(2022YFC2704202);中央高水平医院临床科研业务费(2022-PUMCH-B-083)。

摘　　要：卵巢癌是恶性程度最高的妇科恶性肿瘤之一,通常患者确诊时已为晚期,严重威胁女性健康和生命安全,其治疗也一直是妇科肿瘤领域的重点和难点。卵巢上皮性癌是卵巢恶性肿瘤中最常见的类型。本文旨在回顾2024年度卵巢癌相关的重要临床研究,重点对2024年度卵巢上皮性癌研究结果进行盘点,包括免疫治疗、抗体药物偶联物治疗、手术治疗等,以期为卵巢癌的治疗和长期管理提供参考。Ovarian cancer is one of the most malignant gynecological malignant tumors,patients are usually diagnosed at an advanced stage,which seriously threatens women's health and life safety.Its treatment has always been the focus and difficulty in thefield of gynecological tumors.Epithelial ovarian cancer is the most common type of ovarian malignant tumors.This paper aims to review the important clinical studies related to ovarian cancer in 2024,and to review the research results of epithelial ovarian cancer in 2024,including immunotherapy,antibody-drug conjugate,and surgical treatment,in order to provide a reference for the treatment and management of ovarian cancer.

关 键 词：卵巢癌 卵巢上皮性癌 免疫治疗 抗体药物偶联物 

分 类 号：R73[医药卫生—肿瘤]